Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Ohio

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Literacy to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medication safety and disease prevention. In this legacy context, audiences have been educated about the importance of informed consent, adverse event reporting, and the balance between therapeutic benefit and potential harm. This broad framework has empowered individuals to engage with medical guidance while remaining alert to emerging risks. As the landscape of pharmaceutical litigation evolves, a specific area of concern has come into focus: the prolonged use of bisphosphonate medications, such as Fosamax, and their association with rare but serious bone complications. In occupational settings—particularly among healthcare professionals, dental practitioners, and patients with prolonged exposure to these drugs—the risk of osteonecrosis of the jaw has prompted heightened vigilance. This transition from general health literacy to a targeted occupational exposure concern underscores the need for precise legal and medical awareness. For those affected in Ohio, understanding the statute of limitations for filing a Fosamax-related claim becomes critical. The shift from broad health education to specific exposure risk requires careful navigation of both clinical timelines and legal deadlines, ensuring that individuals can act within the prescribed window while maintaining the neutral, evidence-informed perspective that legacy health communication has long championed.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Medical Risk Context and Legal Considerations for Ohio Patients

The incidence of ONJ is considered rare. In a study examining bisphosphonate use, the incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). From a medical risk perspective, the adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, describing the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients and healthcare providers should be aware that ONJ can occur even without identifiable risk factors, and the timeline between exposure and documented harm can be variable, ranging from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients in Ohio considering legal action, attorney-related considerations include the statute of limitations for filing a claim. The statute of limitations for personal injury claims in Ohio is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. Given the variable onset of ONJ symptoms, the timeline between exposure to Fosamax and the diagnosis of ONJ is a critical factor in determining when the statute of limitations begins. Patients should consult with a qualified attorney to assess their individual circumstances, including the date of diagnosis and the date they became aware of the potential link between Fosamax and their condition. In summary, Fosamax is associated with a rare but serious risk of osteonecrosis of the jaw, with onset of symptoms ranging from one day to several months after starting the drug. Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies, and poor oral hygiene. The prescribing information provides warnings and recommendations for management, including discontinuation of the drug for severe symptoms and before invasive dental procedures. Patients in Ohio who have developed ONJ after using Fosamax should be aware of the statute of limitations for filing a claim and seek legal advice promptly.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Ohio?

In Ohio, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For ONJ, the onset of symptoms can vary, so the timeline between Fosamax exposure and diagnosis is critical. Patients should consult an attorney to determine the applicable deadline based on their specific circumstances.

What are the known risk factors for osteonecrosis of the jaw from Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.